Anthrax is an infection caused by bacteria which should be treated and eliminated. And this is the primary goal of the Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a multinational biopharmaceutical company which was founded in 1998. Its very mission is to protect life. The company commercializes, develops, and manufactures therapeutics and vaccines which is mainly concerned about the condition of the immune system. This immunobiotics or advanced vaccines are essential to treat and prevent some diseases. One of the company’s most popular products is the BioThrax. This product is the only FDA-approved anthrax vaccine in the USA. The product is usually delivered to the department of Health and Human Services (HHS) as well as to the Department of Defense. Emergent is now working on vaccines and therapies dealing with Group B strep, hepatitis B and typhoid for commercial market.
Emergent BioSolutions Inc., is inevitably also has competitors in the biotechnology market. These competitors are producing and developing the same products. But compared to any other pharmaceutical companies, the drugs being developed and commercialized by the Emergent BioSolutions Inc. is cheaper and more effective. The ability to provide more efficient and low-priced pharmaceutical products will give the company an advantage in terms of financial success.
In terms of stock, Emergent BioSolutions Inc. has $12.49 on price. And to be able to firmly stay on its stable position, the company should continue to fully develop its studies concerning hepatitis B for this will bring them success in the future. But, as of now, it is safe to say that the throat defender against anthrax is the Emergent BioSolutions Inc.